Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Merozan is a formulation of pentosan polysulfate developed by Meroven for the treatment of Bladder Pain Syndrome (BPS) and Interstitial Cystitis (IC). As a heparin-like, sulfated polysaccharide, it functions as a bladder mucosal protectant. The drug is thought to work by replacing or repairing the deficient glycosaminoglycan (GAG) layer of the bladder wall, thereby restoring the protective barrier and preventing urinary irritants from reaching the underlying tissue, which relieves bladder pain and discomfort. Merozan is uniquely designed for dual administration via both oral and intravesical routes and has achieved approved status for its primary indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Merozan.